Introduction
Blood group ABO antigens are present both as glycolipids and as glycoproteins on the red cell membrane. These antigens are quantitatively expressed in a serologically defined manner, with 80% of blood group A Europeans having very strong A antigen expression and 20% having moderate A antigen expression, representative of the A 1 and A 2 red cell phenotypes, respectively (Economidou et al. 1967; Schachter et al. 1973; Schenkel-Brunner 2000) . A series of much lessfrequent weak A subgroup red cell phenotypes each with decreasing blood group A antigen from A int , A 3 , A x , A end , A m , A finn , A bantu , A lae , A y to A el are also recognized. The N-acetylgalactosaminyl transferase encoded by the blood group A gene was mapped in 1990 (Yamamoto et al. 1990) , and thereafter studies have established an enormous heterogeneity between and within the subgroups (Olsson and Chester 1996; Olsson et al. 2001) . In most cases, subgroups are due to recognized genetic mutations (Olsson et al. 2001 ); however, not all subgroups can be adequately explained by mutations within the ABO gene. In particular, with the exception of the A 3 sample in this paper, all other A 3 phenotyping individuals reported to date do not have a recognized ABO gene mutation (Olsson et al. 2001) .
Unlike the relatively well-investigated qualitative and quantitative differences in A antigen expression between the common A 1 and A 2 red cell phenotypes (Schachter et al. 1973; Clausen, Levery, Nudelman et al. 1985; Svensson et al. 2009 ), the qualitative differences of the weak A subgroups are still largely unexplored. Studies with electron microscopy of immunogold-labelled red cells and immunochemistry of glycolipids indicate that the weak A subgroups differ from A 1 and A 2 both in the number of antigens present and by their chemical nature (Heier et al. 1994; Svensson et al. 2005 ). The weak A subgroup known as the A 3 phenotype is one of the more unusual A subgroups as it is defined by the serological reaction referred to as mixed-field agglutination: "small agglutinates in a sea of free unaggutinated cells" (Klein and Anstee 2005) . One recent flow cytometry study also showed that there appears to be two populations of A cells in the A 3 phenotype, although the A 3 sample in this paper (albeit with a different genetic basis) in the same study was an exception with only a single population of A cells (Hult and Olsson 2010) . Further evidence to support dual populations in the A 3 phenotype comes from the observation that A glycosyltransferase activity could only be found in the stroma of A 3 agglutinates (Nakamura et al. 1989) . Interestingly, early studies of A 3 mixed-field reactions found that the unagglutinated cells were agglutinable when retested with anti-A (Cartron et al. 1977) , and despite no genetic evidence for an aberrant glycosyltransferase, 13 A 3 individuals were found to have an A glycosyltransferase with a different pH optima than that of the A 1 glycosyltransferase (Nakamura et al. 1989) .
Determining the structural basis of unusual phenotypes, or the insight they may give of background structures not usually accessible for identification in the presence of normal and dominating antigens, is of importance to understanding the biology of blood group antigens. Subgroups provide a unique insight into the biosynthesis of ABO antigens, or at least alternative biosynthetic pathways which may operate under certain biological pressures. This paper describes a comprehensive biochemical and structural analysis of glycolipids isolated from one individual with a well-defined A 3 phenotype. The structural analysis is based on complementary structural profiling involving nuclear magnetic resonance (NMR), mass spectrometry (MS) and thin layer chromatography (TLC) techniques. The data corroborated a previous study of this individual (Aweak-II), which revealed an A 3 phenotype, with a new genetic mutation (A304 in Blood Group Antigen Gene Mutation Database; Blumenfeld and Patnaik 2004) , and an unusual total neutral glycolipid profile (Svensson et al. 2005) . To distinguish the sample of this paper from the undefined ABO genetic background A 3 samples, hereafter it is termed the A304 A 3 phenotype.
Results

Confirmation of mixed-field agglutination phenomenon
The red cells of the A304 A 3 sample were subjected to extended differential serology to prove the nature of the mixed-field agglutination ( Figure 1 ). As expected, the A304 A 3 sample (lane I) showed the classic mixed-field reaction of both agglutinating and non-agglutinating cells. When the agglutinating (lane II) and non-agglutinating cells (lane III) were purified and then retested with new reagents, both again showed the mixed-field agglutination reaction. (Figure 2 , lane A 1 ) both Aweak-II samples (T* and T) reacted similarly against anti-A 2-22, albeit quantitatively reduced in reactivity, despite being loaded at a 2.5 times higher concentration. However, against anti-A type 2 reactive monoclonal antibodies (MAbs) 2-24 and HH4, staining was unambiguously reduced. Anti-AB 2-41 was unreactive in the six-sugar region but showed significant reactivity in the extended glycolipid regions in agreement with previously reported data (Svensson et al. 2005) . Reactivity against three anti-B reactive reagents confirmed this reactivity was not due to B structures (results not shown). The anti-A type 3 reactive MAb TH1 revealed no bands in the regions expected for A type 3 glycolipids.
Reactivity against anti-H type 3 MAb (HH14) and anti-H type 2 (BE2) showed a pattern similar to a blood group A 2 phenotype control (result not shown).
Chemical staining of the medium-pressure liquid chromatography fractions The medium-pressure liquid chromatography (MPLC) separation of the total neutral glycolipids resulted in seven fractions, each containing mixtures of complex glycolipids of increasing size, and persistent contamination with globoside (GbO 4 ) the major glycolipid component in red cells, yet were sufficiently pure for MS and NMR analyses. Anisaldehyde semi-quantitative chemical staining (Figure 3 , plate I) showed that fraction 1 included glycolipids with 4-6 sugar residues, whereas fractions 2 and 3 mainly contained 7-12 residues. The dominant structures in fractions 4 and 5 were glycolipids with 8 to approximately 12 sugar residues. Fractions 6 and 7, although poorly resolved, represented the more extended glycolipids with more than 10 sugar residues. Table I shows a summary of the representative glycolipids and weight of each of the seven fractions.
TLC-enzyme immunoassay of the MPLC fractions
The immunochemical staining was repeated on the MPLC fractions at a loading concentration of 10 µg per lane. Glycolipid structures in an A 3 red cell phenotype Fraction 1 (Figure 3 , plate II, lane 1), containing the four to six-sugar-residue glycolipids, stained in the six-sugar region (relative migration, rm 6) with two monoclonal A antigen reactive reagents and the lectin Helix pomatia. With due consideration to the semi-quantitative nature of TLC-enzyme immunoassay (EIA), there was significant contrast in band intensity between the strong six-sugar bands with Lorne/ H. pomatia and the moderate band with anti-A 2-24 (Figure 3 , II) and the absence of reactivity with anti-AB 2-41.
Compared with the unfractionated total samples (Figure 2 ), the concentrated glycolipids in the MPLC fractions ( Figure 3 , II and III) could be more confidently immunochemically defined, particularly the presence of A type 2 (Hakomori 1981) and A type 3 glycotopes (Clausen, Levery, Nudelman et al. 1985; Clausen et al. 1986) (Figure 3, III) . As expected, MAb 2-22 was strongly reactive in all fractions (Figure 3, III) and reactivity could be seen indicative of blood group A with 8 (rm 3) and 10/12 (rm 1 ± 0.5) sugar residues and probably para-Forssman (GalNAcβ3GbO 4 , rm 6 ± 0.5) (Ando et al. 1982) . Identity of these structures as A type 2 glycolipids was indicated by their reactivity with the anti-A type 2 reactive MAb (2-24). In addition, very weak reactions seen with anti-A type 3 MAb TH1 suggest the presence of some A-9-3 (rm 3.0) and A-11-3 (rm 0.9) glycolipids in fractions 4 and 5, respectively (Figure 3, III) . Expected glycolipid reaction patterns (when compared with the A 2 phenotype) were observed with anti-H type 2 and H type 3 reactive MAbs (results not shown).
Structural analysis of A glycolipids by nano-electrospray ionization-quadrupole time-of-flight tandem mass spectrometry By nano-electrospray ionization (ESI)-quadrupole time-offlight (QTOF) MS screening, a number of blood group A glycolipid-related ions were detected in fractions 1, 4 and 5 as illustrated in Figures 4-6 and Table II. In total, 19 blood group A glycolipid-related ions based on compositional assignment were detected, indicative of A-6, A-8, A-9, A-10 and A-11 glycolipids. The evaluation of glycolipid molecular ion patterns provided evidence that A-8 structures dominate in number and abundance. The applied ionization conditions prompted the formation of doubly charged ions with a minimal, if any, in-source decay of glycosidic bonds. The A-6 glycolipid (Table II) was exclusively detected in its singly charged form. All ion species detected in the MS1 profile and postulated based on the compositional assignment to correspond to A glycolipids (cf. also Table II) were confirmed by collision-induced dissociation (CID) tandem mass spectrometry (MS/MS) fragmentation analysis. Basically, A-8, A-9 and A-10 type glycolipids were found to dominate the mixture. Sensitivity of the analysis was sufficiently high to allow the detection of very low abundant species, such as A-6 glycolipids.
Nano-ESI-QTOF MS identification of A-6 was initially based on compositional analysis of corresponding singly charged ions at m/z 1711.11 assigned to FucHexNAc 2 Hex 3 Cer(d18:1/24:0). Accurate structural elucidation of the ions at m/z 1711.11 was achieved by CID MS/MS experiments (Figure 4 ) in the second-stage analysis. The resultant fragmentation pattern is unambiguously consistent with the A-6 structure having d18:1/24:0 Cer (Figure 4 , inset scheme). The presence of a terminal fucose (Fuc) residue is easily deducible from the immediate loss of 146 (atomic mass units) from the molecular ions, represented at m/z 1565.02. The fragmentation pathway of the ions at m/z 1565.02 follows a stepwise glycosidic bond cleavage, starting with the monosaccharide residues from the nonreducing end up to the Cer residue, and defining this way the sequence of the main HexNAc-Hex-HexNAc-Hex-Hex-Cer glycosidic backbone. The presence of the ions at m/z 1507.99 corresponding to a neutral loss of the HexNAc residue from the precursor ions clearly indicates the location of HexNAc at the nonreducing end terminus and, at the same time, that there exists a branching point for Fuc attachment within the remaining glycan chain. Given the presence of Y 3 type ions at m/z 1199.83, which defines the Fig. 2 . TLC-EIA of total neutral glycolipids from the Aweak-II A 3 phenotype donor (A304 A 3 ) immunostained with selected blood group A reactive MAbs. The numbers to the right denote the approximate number of carbohydrate residues of the glycolipids in the corresponding band. Lane A 1 , common blood group A 1 phenotype control, 20 μg loading; lane T*, the original Aweak-II glycolipid preparation, 50 μg loading; lane T, new Aweak-II glycolipid preparation from six pooled donations, 50 μg loading. Individual plates were overlaid with either MAb anti-A 2-22, 2-24, anti-A type 2 HH4, anti-AB 2-41 or anti-A type 3 TH1, respectively, and then compiled to create the figure.
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HexNAc-Hex-Hex-Cer(d18:1/24:0) structure, and its counterpart B 2 -type ions at m/z 534.17, the attachment of the Fuc at the terminal Gal residue is clearly revealed. Additionally, the Glycolipid structures in an A 3 red cell phenotype whereas the N″-type ions at m/z 264.28 correlate with the d18:1 long-chain base of the Cer part. Under the fragmentation conditions applied, a number of fragment ions arising from internal double-or triple-glycosidic-bond cleavages were detected, which underscore more of the glycan chain structure: the core disaccharide unit is supported by the ions at m/z 347.12 (B 5 /B 3 ) and the Y 2 -type ions at m/z 996.77; the (Fuc)HexHexNAcHex is indicated by the ions at m/z 696.33, which then undergoes a neutral loss of Fuc to deliver the fragment ions at m/z 550.18.
All other blood group A glycolipid species (listed in Table II ) rendered similar rich fragment ion patterns. An additional example is presented in Figure 5 , where the fragmentation patterns of the doubly charged ions at m/z 1304.58 and the co-isolated ions at m/z 1305.60, respectively, are assigned to Fuc 2 Hex 5 HexNAc 4 Cer(d18:1/24:0,1) based on the theoretical calculation. The resulting fragmentation pattern is consistent with an A-11 structure with (d18:1/24:0) (Figure 6 , I). Given the very low abundance of this species in the original mixture of fraction 5, the MS/MS pattern is remarkably rich and the fragment ions abundance is sufficient to identify the structure. Similar to the A-6 structure, the neutral loss of a HexNAc residue from the precursor ions delivering the fragment ions at m/z 1202.82 (Y 8α ′) indicates the HexNAc as a terminal residue at the nonreducing end. More prominent is the neutral loss of one and two Fuc residues, characterizing the degree of fucosylation of the molecule. Following the loss of HexNAc residue from the precursor ions, the series of Y-type ions starting with the ions at m/z 1048.74 arising from Fig. 4 . Nano-ESI-QTOF fragmentation spectrum of singly charged ions at m/z 1711.11 detected in fraction 5 consistent with FucHexNAc 2 Hex 3 Cer(d18:1/24:0) and assigned to the A-6 glycolipid. Co-isolated are the ions at m/z 1709.10 which correspond to A-6 Cer(d18:1/24:1), giving rise to Y-type fragment ions downshifted by 2 amu (due to the monounsaturated C24 fatty acid) compared with the ions derived from precursor at m/z 1711.11. Inset: Fragmentation scheme of the A-6 glycolipid with Cer(d18:1/24:0). the subsequent neutral loss of FucHex, and ending with Y 1 -type ions, HexCer, essentially concludes the carbohydrate chain structure of an A-11 glycolipid. The HexNAc-HexHexNAc-Hex-Hex-Cer structure represented at m/z 1565.18 is extended by two HexNAc-(Fuc)Hex units, which is typical for an A-11-3 structure. The fragment ions at m/z 1873.30 along with the fragmentation of ions at m/z 1202.78 to 1048.74, respectively, clearly point to the attachment of two Fuc residues at the first two Hex residues in the glycan chain at the nonreducing end. These structural elements along with the B-type ions, B 2α (HexNAc-(Fuc)Hex) and B 3α (HexNAc-(Fuc)Hex-HexNAc) and a considerable number of internal double-and triple-glycosidic-bond cleavages ( Figure 6 , I) represent a reliable set of fingerprint ions for diagnosing an A-11-3 structure. An interesting feature revealed by data interpretation from Figure 5 is the existence of structural elements corresponding to an overlapping, isobaric structure, other than A-11. The fragment ions at m/z 1150.33 related to a neutral loss of a FucHex residue from the precursor ions along with the ions derived by the subsequent neutral loss of the second Fuc residue at m/z 1077.25, and the ions at m/z 1768.09 supporting the HexNAc-HexNAc-Hex-HexNAc-Hex-Hex-Cer fragment reveal the existence of another species, as depicted in Scheme II ( Figure 6 ). Even though at very low abundance, these peaks depict a reliable isotopomer pattern for their identification and assignment. In this configuration (Scheme II in Figure 6 ), a repeating (Fuc)Hex-HexNAc motif at the nonreducing end terminus extends the HexNAcHex-HexNAc-Hex-Hex-Cer core structure at m/z 1565.18, indicating a seemingly extended X 2 -type glycolipid. The presence of X 2 glycolipid was also detected by NMR (Table III) , while structural elements suggestive for other members of extended X 2 glycolipid series were also found to interfere with other blood group A glycolipid fragmentation patterns. A more detailed study of such an extended X 2 glycolipid as well as of extended GalNAcβ3GbO 4 series (data not shown) will be undertaken in the near future to comprehensively identify the number and type of the structures in the series.
Structural analysis of A glycolipids by proton NMR The proton NMR ( 1 H-NMR) spectrum of fraction 1 is shown in Figure 7 and identified structures and references (Clausen, Levery, McKibbin et al. 1985; Holgersson et al. 1990; Thorn Fig. 5 . Nano-ESI-QTOF fragmentation spectrum of doubly charged ions at m/z 1304.58 detected in fraction 5 consistent with Fuc 2 HexNAc 4 Hex 5 Cer(d18:1/24:1) and assigned to the A-11 glycolipid. Co-isolated are the ions at m/z 1305.60 which corresponds to a glycolipid with 11 sugar residues and Cer(d18:1/24:1), giving rise to Y-type fragment ions up shifted by 2 amu compared with the ions derived from precursor at m/z 1304.58. Fragmentation patterns are also consistent with an isobaric structure, possibly an extended X 2 glycolipid.
Glycolipid structures in an A 3 red cell phenotype Teneberg et al. 1994; Angstrom et al. 2004; Miller-Podraza et al. 2005 ) are summarized in Table III (Breimer et al. 1982; Bjork et al. 1987 ). An intermediate contribution attributed to neolactotetraosylceramide and/or neolactohexaosylceramide (nLc-4 and/or nLc-6) is also deduced from the intensity of the GlcNAcβ3 resonance at 4.65 ppm which Table IV . Most noticeable is the dominating presence of GbO 4 and H-7-2/H-9-2 in all four fractions whereas blood group A type 2 structures are evident in very small amounts having 8 or 10 sugar residues. All other structures are also present in very small amounts except for an extended form of P 1 , which is present approximately in the same amount as the H structures in fraction 4. Evidence for a second extended structure stems from the observed perturbations of the anomeric shift of the terminal GalNAcβ3 residue of GalNAcβ3GbO 4 in fraction 2. However, the nature of this extension from an NMR point of view is unclear at present. As expected, the extension of H-5-2 by one or two lactosamine fragments yielding H-7-2 and H-9-2 is present as are the structures H-8-3 and H-10-3 which are precursors for the similarly found A-9-3 and A-11-3 structures. It should be noted that only the signature resonances stemming from the glycotope residues have been recognized for different A and H structures. No additional or informative spectra were obtained from fractions 6 and 7. Novel glycolipid structures not related to blood group A, such as series of extended GalNAcβ3GbO 4 , extended X 2 and extended P 1 glycolipids were detected by both proton NMR and MS (Table IV) .
Discussion
The A 3 phenotype is rare occurring with a frequency of <1:1000 (Klein and AD 2005) and was recognized many years ago as one of the more unusual subgroups of A, essentially because it is characterized not only by weak expression of A antigen but also a co-requirement of the serological phenomenon called mixed-field agglutination. Over the last decade, a genetic basis for many of the ABO subgroups has been resolved, but the A 3 genotype is still undefined with almost all individuals reported today having normal ABO genotypes. This suggests that genes outside the ABO locus maybe responsible for the phenotype of reduced A antigen and mixed-field agglutination. However, the individual of this study is more unusual than other A 3 's in that it does have an ABO genetic mutation and by flow cytometry it does not show the dual population of cells seen in other A 3 's (Hult and Olsson 2010). These observations suggest that there may be two different mechanisms leading to the A 3 serological phenotype. The first is the more common A 3 with an undefined ABO genetic background and a dual population of cells, whereas the second is the A 3 of this paper with a novel A304 allele (called here the A304 A 3 phenotype) (Svensson et al. 2005) and only a single population of cells identified by flow cytometry. The glycolipids of this sample A304 A 3 were originally studied and found to be unusual compared with other subgroups of A in that it appeared to lack the otherwise dominant A-6-2 glycolipid and an extended glycolipid, together with evidence of novel blood group A structure(s) (Svensson et al. 2005) . So far glycolipids from undefined ABO genetic background A 3 individuals with normal ABO alleles have not been studied, but it is suspected that their glycolipid profile may be different from the A304 A 3 individual. All the same, the A304 A 3 sample provides an insight into an alternative biochemical explanation for the A 3 phenotype and in particular mixed-field agglutination.
In an attempt to elucidate the biochemical nature of the A 3 phenotype or at least that of the A304 A 3 phenotype and in particular mixed-field agglutination, glycolipids from approximately 1 kg of packed red cells were extracted and purified so as to be suitable for structural analysis. Unlike the study of blood group antigens in common phenotypes, the study of weak subgroups is severely compromised by virtue of the fact that the blood group molecules are present in only very low concentrations, estimated at less than 5% of normal. Consequently, obtaining sufficient material of adequate purity Table III. Glycolipid structures in an A 3 red cell phenotype for a structural analysis, particularly NMR spectroscopy, is demanding. Unfortunately, confounding issues posed by the poor solubility of purified extended glycolipids severely compromises the ability to obtain optimal levels of purity, and instead fractions containing mixtures of glycolipids have to be used. However, by using three independent techniques, complementary advantages were exploited: TLC with immunochemical detection defined the approximate size and type of the glycotope(s) with a variety of monoclonal reagents; MS analysis with high sensitivity determines the existence of lowabundance structures and provides the structural architecture of glycolipids; proton NMR including 2D methods allows the identification of specific sugars and linkage signatures. It should be noted that, by tandem MS analysis of underivatized A type glycolipids, the discrimination between Galβ3 and Galβ4 linkages is not achievable, as ring cleavage or differential fragment patterns are not readily obtainable. Derivatization methods such as permethylation (Domon et al. 1990) were not explored in this study due to the increased complexity this procedure would introduce to already highly heterogeneous mixtures. Chain type as either 2 or 3 was therefore determined by immunochemistry and NMR. Nevertheless, given the fact that A type 3 chains are doubly fucosylated, whereas A type 2 chains are monofucosylated (for species with the same number of monosaccharide residues), and experimental conditions were applied to preventing in-source defucosylation, the type of the A chain could be postulated from tandem MS as well. By combining the results of all methods, an accurate and confident identification of the red cell glycolipids of this A304 A 3 phenotyping individual was possible even for complex glycolipid molecular species present in trace amounts.
It was fortunate that this A304 A 3 individual was an ABO non-secretor, thereby eliminating the presence of type 1 A structures acquired by red cells from plasma from the interpretations. There are five significant observations related to the glycolipids of this individual. First, relative to the A 1 / A 2 phenotype, there are very low levels of blood group A glycolipids, which is expected as this is a requisite of a weak A phenotype. Second is the below-detection limits of A-6-2 in the total glycolipid fraction even when compared with the A x subgroup (Svensson et al. 2005) . Only in the purified fractions could A-6-2 be confirmed by both MAb 2-24 (Figure 3, II) and structural analysis (nano-ESI-QTOF MS (CID MS/MS) and NMR). Third was the confirmed presence of GalNAcβ3GbO 4 , which stained with certain anti-A reagents (2005) The identity of the anomeric proton resonances are given in the NMR spectrum shown in Figure 7 .
a Chemical shift values are not given due to severe resonance overlap but can be found in the literature references given above.
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at the six-sugar interval, was present in extended forms and was identified by structural MS analysis through specific fragment ions corresponding to HexNAcHexNAcHexHexHexCer sequence and its extensions. Initially, it was considered that the GalNAcβ3GbO 4 antigen could be contributing to the A 3 phenotype; however, since this structure has been found in pools of red cell membranes of all ABO types (Ando et al. 1982; Angstrom et al. 1986) , it is unlikely to be the cause of the A 3 phenotype. Surprisingly, when we immunostained total glycolipid fractions from blood group B and O individuals with the GalNAcβ3GbO 4 reactive anti-A (MAb 2-22), we were also able to clearly identify GalNAcβ3GbO 4 bands in 6/ 6 B samples but in only 1/5 O samples (results not shown). It is possible to speculate that this could be due to an alternative substrate/precursor activity of the B and A304 A 3 glycosyltransferases, and in the case of some O samples, a nontruncated enzyme incapable of utilizing H but still active against globotetraosylceramide, but this remains highly speculative. On the basis of these observations and the literature, it seems evident that GalNAcβ3GbO 4 antigen does not contribute to the A 3 phenotype but remains an important antigen to consider when using anti-A reagents by very sensitive techniques such as flow cytometry and TLC-EIA. The fourth observation was the presence of most of the expected extended structures, including A-8-2, A-10-2, A-9-3 and A-11-3. Why these extended structures should still be synthesized, when the usually more dominant A-6-2 glycolipid is poorly represented, is an interesting question-and one which remains unresolved. The fifth was both the absence of an extended structure and no evidence for any branched blood group A glycolipids in the MS spectra, which raises the possibility that the absent extended structure may have been branched. After excluding recognized dual-cell population reasons for mixed-field agglutination, namely chimerism, transfusion, transplantation, fetal maternal bleeds or disease, the diagnosis of the A 3 phenotype is solely on the basis of mixed-field anti-A serological agglutination of red cells with reduced A antigen expression. Intriguingly, flow cytometry has reasonably suggested that dual populations of cells may be an explanation for the mixed-field reactions observed (Hult and Olsson 2010) . This is also supported by findings that the A glycosyltransferase is found only on agglutinated cells (Nakamura et al. 1989) . Unfortunately, this dual population explanation for mixed-field agglutination does not hold for this A304 A 3 sample, as in the same flow cytometry study (Hult and Olsson 2010) , it did not have a dual population. Additional complexity is suggested by early observations that A 3 cells initially not agglutinated in the mixed-field reaction will agglutinate when secondarily reacted with anti-A. We were also able to confirm this unusual phenomenon of A 3 red cells with this A304 A 3 sample and serological gel cards. Although the glycolipids of this A304 A 3 individual may not be typical of all A 3 phenotypes this individual unambiguously has A 3 serology of reduced A antigen and mixed-field agglutination. Consequently, an alternative explanation for mixed-field agglutination, not dependent on a dual-cell population, is needed. This requires a population of cells to start with a low antigen count close to the positive/negative agglutination threshold. If that population of cells is then also missing some or most of its branched structures, then the binding strength of antibodies to them would be compromised (a phenomenon well recognized in the serology of newborns; Clausen and Hakomori 1989) . When external shear forces are then applied in serological reactions, it would be reasonable to expect that many of the cells less strongly bound in the agglutinates would shear away as free cells and result in a mixed-field reaction. Such a postulate is also compatible with the observation that the free cells when recovered are agglutinable by antibody.
Overall, we can confidently state that the glycolipid anomalies of this A304 A 3 individual was a very low abundance of A structures, particularly A-6-2 and an absence of branched A glycolipids. The contribution of the glycoproteins or polyglycosylceramides was not able to be considered. It is speculated that the low level of A antigen combined with an absence of extended branched glycolipids may be the factor determining the mixed-field agglutination phenomenon, at least in this A304 A 3 individual.
Materials and methods
Blood donor
Six blood donations totaling approximately 1.0 kg of concentrated red cells were collected over the period of 2 years from the original donor (Aweak-II) with the A 3 (anti-A mixed field), P 1 , Le(a+b−) ABH non-secretor phenotype and the A 2(539G>A) /O 1 genotype as previously reported (Svensson et al. 2005) . Red cell units at the supplying Blood Centre were leukocyte-depleted by filtration, washed free of plasma with buffered isotonic saline and stored frozen at −20°C until ready for processing.
Mixed-field agglutination serology A304 A 3 red cells were tested against Novaclone murine monoclonal anti-A (Galileo; Dominion Biologicals Limited, Dartmouth, Nova Scotia, Canada) in a saline Diamed gel card system (DiaMed, GmbH, Cressier FR, Switzerland) and separated by centrifugation according to normal serological procedures. Following centrifugal separation, the agglutinated (+) cells from the upper part of the gel were recovered from the unagglutinated (−) cells from the lower part of the gel. Cells were recovered from several gel cards, washed, concentration adjusted and then reacted again in the original system against new reagents. Blood group O and A 2 cells were tested in parallel as controls (not shown).
Neutral glycolipids
The glycolipids from the thawed hemolyzed red cell pool were extracted via a system of solvents and silica/ion exchange chromatography as previously described (Svensson et al. 2005) , resulting in 250 mg of total neutral glycolipids. It should be noted this method does not isolate polyglycosylceramides, i.e. those with >20 sugar residues.
The total glycolipid mixture was subjected to TLC, chemical or immunochemical staining analyses, and 200 mg was further refined by column chromatography (open column as well as MPLC).
Glycolipid structures in an A 3 red cell phenotype
The terminology used to describe glycolipids is as recommended by IUPAC-IUB (Chester 1998) . The abbreviation, for example, A-6-2 stands for blood group (group A), the number of carbohydrate units (six saccharides) and the type of core structure (type 2) of the glycolipid (Holgersson et al. 1992) . With respect to Cer, for example, d18:1/24:0 means a dihydroxy long chain base with 18 carbon atoms and one double bond combined with a saturated non-hydroxylated 24-carbon atom fatty acid.
Medium-pressure liquid chromatography Two hundred milligrams of total neutral glycolipids were separated into 20 fractions by the Büchi Sepacore™ Flash system (Büchi Labortechnik AG, Switzerland) using a silica S60 (2050027, SDS, France) packed column. The flow rate was set to 12.5 mL/min. The first two fractions were eluted with a solvent mix of chloroform:methanol:water (CMW) 80:20:1 v/v each after 15 min followed by four more fractions eluted with CMW 70:25:4 v/v at 10 min intervals. Ten fractions were then eluted with CMW 60:35:8 v/v at 5 min intervals and two further fractions at 10 min intervals. Two final fractions were eluted with CMW 40:40:12 v/v at 20 and 10 min intervals, respectively. Following TLC analysis (chemical and immunochemical), the first nine fractions were found to contain no significant blood group glycolipids or only short chain compounds (less than five residues) and were not analyzed further. The remaining fractions were pooled into seven fractions according to TLC mobility (Table I ) and then subjected to extended immunochemical analysis and structural characterization by MS and proton NMR spectroscopy. No attempts to further purify these fractions were made due to the low solubility in the solvent systems used and the risk of irreversible loss of individual components-a phenomenon previously reported during the purification of glycolipid components (Angstrom et al. 1986 ).
Thin layer chromatography TLC plates (HPTLC Silica gel 60 aluminum sheets; Merck, Darmstadt, Germany) were loaded with 10, 20 or 50 µg of glycolipids per lane and separated in a solvent system of CMW 60:35:8 v/v. The air-dried plates were either chemically visualized with anisaldehyde (Karlsson 1987) or by immunochemistry (TLC-EIA) (Schnaar and Needham 1994; Svensson et al. 2005) .
TLC-enzyme immunoassay TLC-EIA involved staining TLC (CMW 60:35:8 v/ v)-separated glycolipids with characterized primary murine MAbs, followed by alkaline phosphatase-conjugated antimurine immunoglobulin (A0162; Sigma, St. Louis, MO) and BCIP/NBT chromogenic substrate (B5655; Sigma) (Schnaar and Needham 1994; Svensson et al. 2005) . A similar protocol was used for immunostaining with biotinylated H. pomatia lectin, which detects GalNAcα residues (L6512; Sigma) diluted at 1:1000 except the secondary detection was with alkaline phosphatase-conjugated streptavidin (S2890; Sigma).
The blood group A, AB and H MAb reagents used for TLC-EIA and their reported specificities are listed in Table V ( Young et al. 1981; Clausen, Levery, Nudelman et al. 1985; Hirohashi et al. 1985; Le Pendu and Henry 2002; Svensson et al. 2005 ). Blood group B MAb reagents used are anti-B (DAKO Corporation, Carpinteria), HEB-29 (GeneTex Inc., Irvine) and MAb 035 (4th International Workshop on Monoclonal Antibodies Against Red Cells and Related Aantigens).
The specificity of the broadly reactive MAb 2-41 and the anti-A type 2 MAb 2-24 was further investigated, and it was found that both were unreactive with pure NMR-verified GalNAcβ3GbO 4 pentaglycosylceramide (Ando et al. 1982) , which migrates in the hexaglycosylceramide region on the TLC plate. In contrast, the other broadly reactive antibodies MAbs 2-22 and MAb "Lorne" (result not shown) were both strongly reactive with this GalNAcβ3GbO 4 structure (Figure 3 , plate IV). On this basis, if a glycosylceramide present in hexaglycosylceramide region was reactive with MAbs 2-22 or "Lorne" but unreactive with MAb 2-41, it was considered strongly indicative of the presence of GalNAcβ3GbO 4 .
Rm scale Rm scales are included in all TLC-EIA plates to indicate the relative position of various bands. The scale was set with 0 as the origin and rm 6 for blood group A hexaglycosylceramide (Svensson et al. 2005 ).
Nano-ESI-QTOF MS and tandem MS
MS experiments were conducted on an orthogonal time-offlight mass spectrometer (Micromass, UK) equipped with a nano-ESI ion source. For data acquisition and processing, the MassLynx software (Micromass) was used. The gas-phase ions were generated from solution using an in-house pulled glass capillary. The ESI voltage was applied onto a metal wire inserted in the glass capillary.
All fractions were prepared to a stock concentration of 1 µg/µL in different solvent systems systematically The mass spectrometer was operated in a positive-ion mode at electrospray potentials between 1000 and 1200 V. Sampling cone potential was ranged between 35 and 55 V for fractions 5 and 4 to enhance the ionization of large molecules and prevent in-source glycosidic bond cleavages, particularly the labile Fuc linkages. For fraction 1, the sampling cone potential was varied between 65 and 120 V given the presence of shorter glycolipids. For structural elucidation, CID tandem MS experiments were performed employing collision energy values between 45 and 160 eV depending on the ion type, to obtain a comprehensive fragment ion pattern for an accurate structural identification. The collision gas pressure was set to 15 psi for all MS/MS experiments. All mass spectra were externally calibrated using a NaI solution.
The tandem MS data assignment followed the nomenclature established by Domon and Costello (1988) .
Proton NMR spectroscopy Intact non-derivatized glycolipid samples were dissolved in dimethylsulfoxide:D 2 O, 98:2 (v:v) after deuterium exchange and spectra were acquired on a Varian 600 MHz spectrometer at 30°C. Both 1D and 2D double quantum-filtered correlated spectroscopy (Marion and Wuthrich 1983) proton NMR were performed. An extensive library of reference chemical shift data at the temperature of choice (30°C) for previously isolated pure glycosphingolipids representing practically all resonances of the structures in Table III was available 
